FindTrial
Sign In

Comparison between Measles-Rubella (MR) Vaccine and Purified Protein Derivative (PPD) injection in warts treatment.

Comparative study between intralesional Measles-Rubella (MR) vaccine versus Purified Protein Derivative(PPD) in treatment of cutaneous warts

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/06/034219
Enrollment
100
Registered
2021-06-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B079- Viral wart, unspecified

Interventions

Intervention1: Measles-Rubella (MR) vaccine: 0.5 ml of intralesional Measles-Rubella (MR) vaccine, using an insulin syringe, at a gap of 2-weeks interval until complete clearance of cutaneous warts or

Sponsors

Dr Manish Kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Patients with recalcitrant or recurrent or multiple or resistant to treat cutaneous warts. b. Patients, where first and second line of treatment have produced no effect. c. Patient of both sexes aged more than 12 years and less than 70 years. d. No concurrent treatment for cutaneous wart

Exclusion criteria

Exclusion criteria: a. Patients with fever or signs of any inflammation or infection b. Patient of both sexes aged less than 12 years and more than70 years c. Pregnancy or planning to conceive. d. Lactation e. Immunosuppression or immunosuppressive disease. f. Ano-genital/ Facial warts. g. Past history of asthma, allergic skin disorders, meningitis, convulsions, hypersensitivity to any antigens.

Design outcomes

Primary

MeasureTime frame
The response will be evaluated as: a.Complete clearance- if there is disappearance of the cutaneous wart and appearance of normal skin b.Partial response - if there is more than 50% reduction in size. c.Minimal response - if the reduction in size is less than 50%. d.No response Timepoint: The response (outcome) will be assessed at a gap of 2-weeks interval until complete clearance or for a maximum of 5 treatments.Follow up of patients will be done for 3 months for clinical assessment of results and to see and check for any recurrence.—

Secondary

MeasureTime frame
1.Resolution of distant untreated warts will also assessed. 2.safety and adverse effects of intralesional Measles-Rubella (MR) vaccine and Purified Protein Derivative (PPD) in treatment of cutaneous warts will be assessedTimepoint: The response (outcome) will be assessed at a gap of 2-weeks interval until complete clearance or for a maximum of 5 treatments.Follow up of patients will be done for 3 months for clinical assessment of results and to see and check for any recurrence.—

Countries

India

Contacts

Public ContactDr Manish Kumar

Command Hospital Air Force, Bangalore

debdeep7@gmail.com8249092824

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026